Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Icovamenib - Biomea Fusion

Next Previous
Drug Profile

Icovamenib - Biomea Fusion

Alternative Names: BMF-219; Covalent menin inhibitor - Biomea Fusion

Latest Information Update: 07 Apr 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Biomea Fusion
  • Class Antihyperglycaemics; Antineoplastics; Morpholines; Piperidines; Pyridines; Pyrimidines; Pyrroles; Small molecules
  • Mechanism of Action Menin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Type 1 diabetes mellitus; Type 2 diabetes mellitus
  • Discontinued Acute myeloid leukaemia; Chronic lymphocytic leukaemia; Colorectal cancer; Diffuse large B cell lymphoma; Multiple myeloma; Non-small cell lung cancer; Pancreatic cancer; Precursor cell lymphoblastic leukaemia-lymphoma; Solid tumours

Most Recent Events

  • 31 Mar 2026 Biomea Fusion initiates enrolment in the phase II COVALENT 212 trial for Type 2 diabetes mellitus (Treatment-experienced, Combination therapy) in USA (PO) (NCT07502508)
  • 31 Mar 2026 Phase-II clinical trials in Type 2 diabetes mellitus (Treatment-experienced, Combination therapy) in USA (PO) (NCT07502495)
  • 14 Jan 2026 Biomea Fusion completes the phase-I COVALENT-121 trial (In volunteers) in USA (NCT07254286)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top